Callan Family Office’s Vaxcyte PCVX Stock Holding History

Callan Family Office’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Buy	4,199 +10	+0.2%	+$543	﹤0.01%	1071
2026 Q1	$243K	Buy	+4,189	New	+$227K	0.01%	995

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Callan Family Office's PCVX Position: Q2 2026 in Review

Callan Family Office increased its Vaxcyte (PCVX) stake by 0.24% in Q2 2026, buying an estimated $543 and bringing the position to 4,199 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Callan Family Office first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Callan Family Office held 4,199 shares of Vaxcyte worth $244K as of Q2 2026.
Callan Family Office bought 10 Vaxcyte shares in Q2 2026, an estimated $543.
Vaxcyte made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1071 holding.
Callan Family Office first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.